NCT02673333View on ClinicalTrials.gov

Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

January 11, 2019

Study Completion Date

February 28, 2026

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Pembrolizumab

Trial Locations (2)

10065

Memorial Sloan Kettering Cancer Center, New York

48109

University of Michigan (Data or Specimen Analysis Only), Ann Arbor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER